Lupus Science & Medicine
Figure 1 Pharmacodynamics of mezagitamab in patients with SLE. Receptor occupancy and population change in NK cells (A) and plasmablasts (B) isolated from patient blood. Data expressed as median % change from pretreatment baseline. (C) Dose-dependent, longitudinal alterations in serum IgG levels, expressed as mean % change from pretreatment baseline±SD. SLE, systemic lupus erythematosus.
6
McDonnell SRP, et al . Lupus Science & Medicine 2024; 11 :e001112. doi:10.1136/lupus-2023-001112
Powered by FlippingBook